Diagnostic probes and therapeutics targeting uPA and uPAR

Details Diagnostic probes and therapeutics targeting uPA and uPAR Diagnostic probes and therapeutics targeting uPA and uPAR

2005-05-24

2005-05-24

Jones, Dameron L. (Department: 1616)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S009100, C424S001110, C514S002600

Reexamination Certificate

active

06896870

ABSTRACT:
A uPAR-targeting protein or peptide is diagnostically or therapeutically labeled and used in methods of diagnosis of therapy. The labeled protein or peptide preferably has the following properties: it comprises at least 38 amino acid residues, including residues 13-30 of the uPAR-binding site of uPA; competes with labeled DFP-uPA for binding to a cell or molecule that has a binding site for uPA, and has an IC50value of about 10 nM or less; and is not a fusion protein wherein the uPA peptide is fused to another non-uPA protein or peptide. Preferred molecules are uPA, scuPA, tcuPA, an N-terminal fragment of uPA, residues 1-135, an N-terminal fragment of uPA, residues 1-143, an N-terminal fragment of uPA, residues 1-43; or an N-terminal fragment of uPA, residues 4-43. Detectable labels include a radionuclide, a PET-imageable agent, an MRI-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a phosphorescer, a chemiluminescer or a bioluminescer. The disclosed methods are used to inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or to induce apoptosis, preferably in the treatment of a subject having a disease or condition associated with undesired cell migration, invasion, proliferation or angiogenesis.

REFERENCES:
patent: 0 890 638 (1999-01-01), None
patent: WO 9012091 (1990-10-01), None
patent: WO 9821230 (1998-05-01), None
patent: WO 9948509 (1999-09-01), None
Higgins et al, 1986, Archives of Biochemistry and Biophysics, Vo. 249, No. 2, pp. 418-426.*
Ettore Appella et al., “The Receptor-binding Sequence of Urokinase”, The Journal of Biological Chemistry, vol. 262, No. 10, Apr. 6, 1987, pp. 4437-4440.
Michael Ploug et al., “Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminofen Activator Using a Decapeptide Anatgonist. Evidence for a Composite Ligand-Binding site and a Short Interdomain Separation”, Biochemistry, 1998, 37, 3612-3622.

Affiliated with

Also associated with

Rating

Diagnostic probes and therapeutics targeting uPA and uPAR does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnostic probes and therapeutics targeting uPA and uPAR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic probes and therapeutics targeting uPA and uPAR will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3391694